Skip to contentC
Castle Biosciences Inc
C
CSTLCastle Biosciences Inc Q2 2021 · 10-Q
Revenue$22.76M$22.76M+79.0% vs Q2 2020 Net Income-$8.79M-$8.79MN/M vs Q2 2020 EPS Diluted-$0.35-$0.35N/M vs Q2 2020 Operating Income-$8,810,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Castle Biosciences Inc · CIK 1447362 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,351,000N/M Margins · derivedOperating margin-38.7%−33.6 pt vs Q2 2020
Net margin-38.6%−27.8 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 9, 2021 · 40 d after period end